Rett syndrome and treatments therefore

Patent metadata

Field	Value
Publication number	US-2016193231-A1
Application number	US-201414392297-A
Country	US
Kind code	A1
Filing date	Jun 26, 2014
Priority date	Jun 26, 2013
Publication date	Jul 7, 2016
Grant date	—

Abstract

The present invention provides new strategies for the treatment of Rett Syndrome and other MECP2-associated disorders, including for the identification and/or characterization of useful therapeutic modalities and/or for the stratification of Rett Syndrome patients to identify those more or less likely to respond to a particular therapy. In some embodiments, the present invention defines certain components of metabolic pathways, and particularly of lipid and/or cholesterol metabolism (e.g., biosynthesis) pathways, most particularly of lipid and/or cholesterol metabolism (e.g., biosynthesis) pathways in the brain, as targets useful in the identification and/or characterization of potential Rett Syndrome treatment agents. Among other things, the present invention provides systems for identifying and/or characterizing such agents by contacting them with a system that comprises one or more such metabolic pathway components, and assessing their impact on presence, level, activity, and/or form of one or more indicators (e.g., components, products, and/or markers of the relevant pathway(s)).

First claim

What is claimed is:

1 . A method of treating a MECP2-associated disease, disorder, or condition comprising administering at least one agent or modality that modulates lipid and/or cholesterol metabolism in the brain to a subject in need thereof.

2 . The method of claim 1 , wherein the at least one agent or modality is selected from: a statin, an LXR modulator, a glucose metabolism modulator, a SREBP modulator, a PPARG modulator, and combinations thereof.

3 . The method of claim 2 , wherein the statin is one or more of lovastatin, simvastatin, alorvastatin, rosuvastatin, and fluvastatin.

4 . The method of claim 2 , wherein the LXR modulator is at least one of an oxysterol, an LXR agonist, and/or an RXR agonist.

5 . The method of claim 4 , wherein the LXR modulator is at least one of hypocholamide, T0901317, GW3965, SR9238, 22(R)-hydroxycholesterol, 24(S)-hydroxysterol, 27-hydroxycholesterol, cholestenoic acid and bexarotene.

6 . The method of claim 2 , wherein the glucose metabolism modulator is at least one of a biguanide drug and 2,4-dinitrophenol-methyl ether (DNP-ME) or derivative thereof.

7 . The method of claim 6 , wherein the at least one biguanide drug is selected from: metformin, proguanil, chlorproguanil.

8 . The method of claim 2 , wherein the SREBP modulator is at least one of fatostatin, N-(4-(2-2-propylpyridin-4-yl)thiazol-4-yl)phenyl)methanesulfonamide (FGH10019), SREBP1, and SREBP2.

9 . The method of claim 2 , wherein the PPARG modulator is a thiazolidinedione.

10 . The method of claim 9 , wherein the thiazolidinedione is at least one of rosiglitazone, pioglitazone, troglitazone, netoglitazone, rivoglitazone, and ciglitazone.

11 . The method of any one of the above claims, wherein the at least one agent or modality is administered at least once per day.

12 . The method of any one of the above claims, wherein the at least one agent or modality is administered at least once per week.

13 . The method of any one of the above claims, wherein the at least one agent or modality is administered at least twice per week.

14 . The method of any one of the above claims, wherein the at least one agent or modality is administered subcutaneously, intraperitoneally, intravenously, or orally.

15 . A method of identifying and/or characterizing useful therapeutic agents for the treatment of Rett Syndrome comprising
determining the effect of a candidate therapeutic agent on one or more aspects of lipid and/or cholesterol metabolism in the brain.

16 . The method of claim 15 , wherein the one or more aspects of lipid and/or cholesterol metabolism is cholesterol biosynthesis.

17 . The method of claim 15 , wherein the one or more aspects of lipid and/or cholesterol metabolism is inhibition of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR).

18 . The method of claim 15 , wherein the one or more aspects of lipid and/or cholesterol metabolism is inhibition of squalene monooxygenase

19 . The method of any one of claims 15 - 18 , wherein the effect of therapeutic agents on one or more aspects of lipid and/or cholesterol metabolism is assessed via one or more of a: behavioral test, cognitive test, motor function test, test of one or more physiological parameters, and combinations thereof.

20 . The method of claim 19 , wherein the behavioral test is selected from: acoustic startle response test, pre-pulse inhibition of startle response test, open field activity test, three chamber social interaction test, Home Cage Activity test, and/or combinations thereof.

21 . The method of claim 19 , wherein the motor function test is selected from: rotarod test, open field locomotor activity test, DigiGait monitoring system, and combinations thereof.

22 . The method of claim 19 , wherein the test of one or more physiological parameters is selected from: dual X-ray absorptiometry (DEXA) test, whole body plethysmography breathing test with methacholine challenge, glucose tolerance test, insulin tolerance test, serum cholesterol test, calorimetry test, and combination thereof.

23 . A method of treating Rett Syndrome comprising administering a statin to a subject suffering from or susceptible to Rett Syndrome.

24 . The method of claim 23 , wherein the statin is selected from: lovastatin, simvastatin, atorvastatin, fluvastatin, and combinations thereof.

25 . The method of claim 23 or 24 , wherein the statin is administered at least once per day.

26 . The method of claim 23 or 24 , wherein the statin is administered at least once per week.

27 . The method of claim 23 or 24 , wherein the statin is administered at least twice per week.

28 . The method of any one of claims 23 - 27 , wherein the statin is administered subcutaneously or orally.

29 . A method of treating Rett Syndrome comprising administering a glucose metabolism modulator to a subject suffering from or susceptible to Rett Syndrome.

30 . The method of claim 29 , wherein the glucose metabolism modulator is selected from: a biguanide drug; 2,4-dinitrophenol-methyl ether (DNP-ME), 2,4-dinitrophenol-ethyl ether (DNP-EE), 2,4-dinitrophenol-vinyl ether (DNP-VE), or a derivatives thereof; and combinations thereof.

31 . The method of claim 30 , wherein the biguanide drug is selected from: metformin, proguanil, chlorproguanil.

32 . The method of any one of claims 29 - 31 , wherein the glucose metabolism modulator is administered at least once per week.

33 . The method of any one of claims 29 - 31 , wherein the glucose metabolism modulator is administered at least twice per week.

34 . The method of any one of claims 29 - 33 , wherein the glucose metabolism modulator is administered subcutaneously, intraperitoneally, intravenously, or orally.

Assignees

• Rett Syndrome Res Trust
• Baylor College Medicine

Inventors

• Scheer David
• Justice Monica J

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K31/575 Primary

  substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol · CPC title

• G01N2800/38

  Pediatrics · CPC title

• A61K31/155

  Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2) · CPC title

• A61K49/0004

  Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions · CPC title